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Abstract  
Background: Acquired resistance to BRAF inhibitors (BRAFi) is a near-universal phenomenon 
caused by numerous genetic and non-genetic alterations. In this study, we evaluated the 
spectrum, onset, pattern of progression, and subsequent clinical outcomes associated with 
specific mechanisms of resistance. 
Methods: We compiled clinical and genetic data from 100 patients with 132 tissue samples 
obtained at progression on BRAFi therapy from 3 large, previously published studies of BRAFi 
resistance. These samples were subjected to whole exome sequencing and/or PCR-based genetic 
testing.  
Results: Among 132 samples, putative resistance mechanisms were identified in 58%, including 
NRAS or KRAS mutations (20%), BRAF splice variants (16%), BRAF
V600E/K
 amplifications 
(13%), MEK1/2 mutations (7%), and non-MAPK pathway alterations (11%). Marked 
heterogeneity was observed within tumors and patients; 18 of 19 patients (95%) with >1 
progression biopsy had distinct/unknown drivers of resistance between samples.  NRAS 
mutations were associated with vemurafenib use (p=0.045) and intracranial metastases 
(p=0.036), and MEK1/2 mutations correlated with hepatic progression (p=0.011). Progression-
free survival and overall survival were similar across resistance mechanisms. The median 
survival after disease progression was 6.9 months, and responses to subsequent BRAF and MEK 
inhibition were uncommon (2 of 15; 13%). Post-progression outcomes did not correlate with 
specific acquired BRAFi resistance mechanisms.   
Conclusions: This is the first study to systematically characterize the clinical implications of 
particular acquired BRAFi resistance mechanisms in patients with BRAF-mutant melanoma 
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largest study to compile the landscape of resistance. Despite marked heterogeneity of resistance 
mechanisms within patients, NRAS mutations correlated with vemurafenib use and intracranial 
disease involvement.  
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Introduction 
Nearly half of melanomas harbor a valine to glutamine substitution in codon 600 of the serine-
threonine kinase BRAF (1). These alterations confer constitutive activation of the mitogen 
activated-protein kinase (MAPK) pathway and thereby drive melanoma growth and progression 
(1, 2). Small molecule inhibitors of mutant BRAF (vemurafenib and dabrafenib) induce tumor 
regression and improve survival in melanoma patients compared to chemotherapy (3, 4). 
The development of acquired resistance to BRAFi, however, is a significant obstacle to effective 
targeted therapy. To characterize and overcome acquired resistance, studies have identified 
numerous genetic and non-genetic drivers of resistance involving MAPK pathway reactivation 
and MAPK-redundant signaling. These include NRAS mutations (5), BRAF
V600E/K
 amplification 
(6), alternate splicing of BRAF (7), MEK1/2 mutations (8), PI3K/AKT pathway dysregulation (9, 
10), and overexpression of genes including COT, PDGFRβ, and others (5, 11-13). The 
translational value of these findings has been clearly demonstrated by successful co-targeting of 
BRAF and MEK, which has further improved clinical outcomes compared with single-agent 
BRAFi (14-17).   
Efforts to systematically define the spectrum and frequency of these BRAFi-resistance 
mechanisms have been published recently (18-20). These studies established the high incidence 
of MAPK-reactivating alterations, but identified intra-patient and intra-tumoral heterogeneity of 
resistance, and a sizable subset of resistance unaccounted for by genomic profiling alone. 
Despite the value of these studies, each was limited by sample size to correlate specific 
mechanisms of resistance with corresponding clinical/biologic behavior. Moreover, the different 
studies reported discordant frequencies of particular resistance mechanisms (e.g. NRAS 
mutations). Thus, we combined published data from the three largest studies of acquired BRAFi-
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resistance in 100 melanoma patients to assess the landscape of resistance mechanisms and the 
corresponding clinical characteristics (18-20).   
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Methods 
Patients and Study Design 
Patients (n=100) and progression samples (n=132) were aggregated from previously-published 
studies conducted under IRB-approved protocols. These studies were led by University Hospital 
Essen (Essen, Germany) and the Broad Institute (Boston, MA, USA) (18), Melanoma Institute 
Australia (Sydney, NSW, Australia) (19), University of California, Los Angeles (USA) (20), and 
collaborators. All patients had advanced BRAF
V600
-mutant melanoma and received vemurafenib 
or dabrafenib as first-line MAPK-directed therapy through clinical trials or as commercially-
available therapy. Nearly all patients experienced tumor regression and subsequent progressive 
disease, except seven with primary disease progression. Objective responses and disease 
progression were defined using Response Evaluation Criteria in Solid Tumors (RECIST) version 
1.1 (21). Baseline demographics, treatment duration, overall survival (OS), progression-free 
survival (PFS), prior therapies, and subsequent treatments were obtained by reviewing medical 
records and imaging results.  
Melanoma Samples 
All patients underwent biopsies of melanoma metastases that were present at baseline and 
enlarged on therapy, or arose during treatment. Most had matched pre-treatment biopsies and 
some had multiple biopsies obtained upon disease progression. Specimens were stored as FFPE 
or were snap-frozen per institutional standard operating procedures. Tumor DNA and RNA were 
extracted per institutional protocols.  
Tumor Sequencing 
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Sequencing was performed by whole exome sequencing (WES  in 56% of disease-progression 
samples or PCR-based sequencing in the remainder.  Sequencing of pre-treatment samples 
corresponding to 107 of the progressing samples was performed (81%), including in all WES 
samples. Recurrent “hotspot” mutations in NRAS, MEK1, and MEK2 were assessed in all 132 
progression samples. Quantitative genomic DNA PCR was performed to detect BRAF
V600E/K
 
amplifications in 120 samples (91%). Alternative splicing of BRAF was evaluated by Sanger 
detection of novel exon–exon boundaries in the cDNAs in 86 progression samples (65%). 
Recurrent AKT1 “hotspot” mutations were assessed in all samples, other mutations in the 
PI3K/AKT pathway were evaluated in the WES samples. WES data analysis has been previously 
described (18-20).  Analyses performed in particular tumors are shown in Table S1.  
Resistance Mechanisms 
Mechanisms of acquired BRAFi resistance were limited to molecular alterations that were: 1) 
detected in the progression sample, 2) not present in the pre-treatment sample, or if baseline 
tissue was unavailable, prior establishment as a resistance mechanism had been performed, and 
3) previously validated to confer BRAFi-resistance in vitro (Table S2). Mechanisms proposed in 
other publications as possible drivers of resistance without pre-clinical validation were not 
included.  
Statistical Analysis 
Associations between classes of resistance mechanisms and clinical variables were evaluated 
using multivariable logistic regression models. We classified resistance mechanisms as the 
following: 1) NRAS or KRAS mutations, 2) BRAF amplifications, 3) BRAF splice variants, 4) 
MEK1 or MEK2 mutations, and 5) non-MAPK alterations. The elastic net method was used for 
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variable selection for building multivariable models. The elastic net is a generalization of the 
LASSO (least absolute shrinkage and selection operator), which provides variable selection in 
the p>>N case without being limited by sample size, and improves performance in the case of 
potentially correlated explanatory variables (22). We used the elastic net method for 
prescreening to discard those least contributing variables ignoring the covariance structure due to 
multiple samples in some patients (23).  Following variable selection, generalized linear mixed-
effects models (logit link or identity link depending on outcome variable type) were used for 
coefficient estimates to account for multiple biopsy specimens within patients.  
PFS, OS, and survival after progression were calculated using the Kaplan-Meier method. Due to 
the co-occurrence of alterations among tumor specimens and within patients, each class of 
resistance mechanism was compared against all other patients using the logrank test. Cox mixed 
effects models were used to investigate baseline factors that influenced survival. All analyses 
were conducted using R version 3.1.1.  
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Results 
Patients  
We included 100 patients with 132 progression samples. Patients had a median age of 54 years; 
70% had AJCC stage IV M1c melanoma, and 17% had brain metastases (Table 1).  BRAF
V600E
 
was present in 87% of patients, and BRAF
V600K/R
 in 13%.. Vemurafenib was the BRAFi received 
by 64% of patients and dabrafenib by 36%. The median PFS was 4.7 months (95% CI 3.8–5.6 
months); median OS was 12.8 months (95% CI 10.7-15.0 months). The objective response rate 
was 72%.  
Sequencing and identified mechanisms of resistance 
Validated mechanisms of resistance were identified in 77/132 progressing tumor samples (58%). 
Sixty-four samples (48%) had a single identified resistance mechanism, 9 (7%) had two 
identified alterations and 4 (3%) had 3 or more (Fig. 1A). Among all progression tumors, NRAS 
or KRAS mutations were identified in 26 samples (17% and 2%, respectively), BRAF
V600E/K
 
amplification in 17 (13%), BRAF splice variants in 21 (16%), MEK1/2 mutations in 9 (7%), and 
non-MAPK pathway alterations in 14 (11%) (Table 2).  Of note, the BRAF splice variant was 
assessed in 65% of samples (n=86) and identified in 24% of these, suggesting that this may be 
the most common resistance mechanism. Non-MAPK pathway alterations largely occurred in the 
PI3K-AKT pathway but also included MITF amplification, and overexpression of 
PDGFR/IGF1R. CDKN2A deletion and DUSP4 loss occurred in 3 samples and were not included 
in further analyses given limited sample size. Several candidate “primary resistance” 
mechanisms were identified in pre-treatment samples from patients with primary disease 
progression or short duration of therapeutic benefit and are listed descriptively (Table S1, S3).  
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Heterogeneity of BRAFi resistance mechanisms 
We then investigated the intra-tumor and intra-patient heterogeneity of resistance. Although most 
progression samples had 0-1 detected alterations, 13 progression tumors, had >1 identified 
mechanism of resistance (10%) co-occurring in the same sample. We assessed whether specific 
resistance mechanisms occurred more frequently in isolation or arose concurrently with other 
alterations (Fig. 1B/C). NRAS mutations (20 of 26, 77%), BRAF splice variants (18 of 21, 86%), 
and MEK1/2 mutations (8 of 9, 89%) usually occurred in isolation. By contrast, BRAF
V600E/K
 
amplification (11 of 17, 65%) and non-MAPK alterations (7 of 14, 50%) more commonly co-
occurred in tumors with other genetic changes (p=0.015). Among MAPK-alterations, NRAS, 
KRAS, MEK1, and MEK2 mutations arose in mutually exclusive fashion with each other, 
whereas BRAF
V600E/K
 amplifications overlapped with NRAS mutations (n=3), non-MAPK 
alterations (n=4), and a MEK2 mutation. BRAF splice variants did not overlap with MEK1/2 
mutations or BRAF amplifications. These results may suggest that certain mutations play 
complementary roles in driving resistance (e.g. BRAF
V600E/K
 amplifications and non-MAPK 
alterations) whereas others have redundant signaling functions and are unlikely to co-occur. 
To investigate genetic heterogeneity within individual patients (as opposed to individual tumor 
samples), we evaluated 19 patients who underwent multiple biopsies during or after progression. 
Of these, 10 (53%) had completely distinct resistance mechanisms between separate biopsies, 4 
(21%) had no identified alterations in any biopsy, and only 1 (5%) had the same identified 
mechanism in all progressing tumors (Fig. 2). Four patients (21%) were found to have some 
overlapping but not identical alterations, supporting the evolutionary development of resistance 
(20). Of these 19 patients, 12 had serial tissue acquisition at two distinct time points after 
progression. On average, earlier progression sample had fewer resistance mechanisms compared 
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to the later sample (mean 0.42 vs. 0.83, p=0.054). These results may suggest that mutational 
complexity increases over time on BRAFi.   
Clinical correlation with mechanisms of resistance  
We then investigated whether baseline disease, treatment, and host factors were related to the 
development of particular resistance mechanisms. We developed multivariable logistic 
regression models assessing the impact of age, gender, LDH levels, sites of metastatic disease, 
drug (vemurafenib vs. dabrafenib), number of prior therapies, and burden of disease (RECIST 
sum of  target lesion diameters). Several associations were identified; NRAS mutations occurred 
more often in patients who received vemurafenib (odds ratio 3.53, p=0.045), among patients who 
had received prior therapies (OR 2.57, p=0.003), and in those with brain metastases at baseline 
(OR 4.57, p=0.037). BRAF
V600E/K
 amplifications also arose more frequently in pre-treated 
patients (OR 2.19, p=0.037). No clear associations were identified for other resistance 
mechanisms. The association between NRAS mutations and vemurafenib use is consistent with 
the higher incidence of cutaneous squamous cell carcinomas (cuSCCs) observed with 
vemurafenib compared with dabrafenib (3, 4, 24, 25). These cuSCCs usually harbor RAS 
mutations (26), suggesting that these otherwise similar agents may promote distinct resistant 
subclonal populations.  
Next, we explored the timing and pattern of disease progression associated with particular 
resistance mechanisms. PFS did not significantly vary by group either in multivariable Cox 
regression models or in univariate analyses (Fig S1). Patients without known resistance 
mechanisms also had similar PFS. NRAS mutations were marginally associated with disease 
progression in the brain (OR 3.05, p=0.066) and negatively correlated with progression in the 
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lungs (OR 0.25, p=0.036); MEK1/2 mutations were associated with hepatic progression (OR 
7.61, p=0.011; 6 of 9 patients with MEK1/2 mutations had disease progression in the liver).  
Effects of mechanisms of resistance on survival and response to subsequent therapies 
We then assessed whether specific mechanisms of resistance influenced clinical outcomes 
following disease progression. Median survival following progression was 6.9 months (95% CI 
5.3 – 8.5 months), and no statistically-significant differences were identified between patients 
harboring particular resistance mechanisms (Fig S2). OS from the start of treatment was also 
similar, regardless of the mechanism of resistance identified (Fig S3). Of interest, 6 patients 
experienced overall survival of > 1000 days (PFS range 300-672 days) and 5 had unknown 
drivers of resistance (19).  
Finally, we assessed the influence of resistance mechanisms on response to subsequent therapy 
particularly focusing on MAPK-directed treatment. Fifteen patients received subsequent BRAF 
+MEK inhibition; two experienced partial responses (13%), and no mechanism of BRAFi 
resistance was identified in either patient. Stable disease was observed in an additional 7 patients 
(objective response + stable disease in 9 of 15 patients; 60%) and occurred in patients with 
various resistance mechanisms.. Patients with MAPK-only resistance drivers appeared to have 
more frequent disease stabilization (6 of 8; 75%) compared to patients with non-MAPK 
alterations (1 of 3, 33%). In addition, 21 patients also received ipilimumab following 
progression, and no patients responded (Table S3).  
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Discussion 
In this study, we combined previously-published analyses of BRAFi resistance to form the 
largest cohort (to our knowledge) of 132 BRAFi progression melanoma tissue samples from 100 
patients. This large population allowed us to correlate resistance mechanisms with clinical 
characteristics and outcomes. This study also provides a comprehensive landscape of the 
incidence and heterogeneity of genetic changes driving BRAFi-resistance.  
Acquired resistance is a major hindrance to effective molecularly-targeted therapy. BRAFi in 
particular have been linked to a diverse array of genetic changes driving resistance with unclear 
therapeutic and prognostic implications. Assessing the resistance landscape in a large cohort with 
integrated clinical data has therefore been a critical need. We conclude that NRAS mutations, 
BRAF
V600E/K
 amplifications, BRAF splice variants, and various non-MAPK alterations each occur 
in 11-24% of BRAFi-progression melanomas. We also observed marked tumor heterogeneity; 
although individual progression samples usually harbored only a single resistance mechanism, 
nearly all patients with multiple resistance biopsies had distinct or unknown drivers of resistance 
(95%).  Such marked intra-patient genetic heterogeneity likely limited our ability to correlate 
individual genetic changes with clinical behavior. 
Despite this, we identified clinically-relevant associations. First, resistance changes correlated 
with specific organ involvement in some cases (NRAS mutations and brain metastases; MEK1/2 
mutations and hepatic progression). Second, NRAS mutations occurred more frequently in 
vemurafenib-treated patients, suggesting differences in subclonal activation between BRAFi. 
Third, the similar spectrum of resistance drivers between BRAFi monotherapy and those 
observed with BRAFi/MEKi therapy suggests that these clinical associations may be relevant for 
the now-preferred combination (19, 27-29). Finally, the intra-patient heterogeneity and lack of 
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clear associations with post-progression outcomes implies that genetic profiling from a single 
post-progression biopsy to guide further therapy will be challenging. 
Although this study was not designed to identify novel resistance mechanisms, several biologic 
insights were suggested. Some alterations, including MEK1
P124
 and PTEN mutations appear to 
mediate resistance in a complex, context-dependent fashion. For example, pre-existing MEK1
P124
 
mutations diminished, but did not preclude clinical responses to BRAFi in this study and others 
(30). Conversely, in pre-clinical models, these mutations robustly mediate BRAFi-resistance 
(18). Similar dynamic changes should be considered in other drug-resistance states.  In addition, 
patients with serial biopsies following progression had more alterations in the later post-
progression sample compared to the earlier sample, potentially suggesting increasing mutational 
complexity arising on therapy. Finally, we observed that some resistance mechanisms tended to 
arise in isolation, whereas others tended to co-occur with other drivers, suggesting that particular 
alterations may differ in their ability to drive resistance in vivo.  
Exploring the non-genetic and immune features of BRAFi-resistance will be a crucial next step. 
Despite comprehensive molecular characterization, >40% of tumor progression samples 
harbored no identified resistance drivers, including several patients with multiple progression 
samples analyzed by WES. Non-genetic (epigenetic) or transcriptome-based changes likely drive 
resistance in this substantial cohort. In addition, no patients responded to ipilimumab after 
BRAFi-failure, corroborating previous findings (31, 32). Thus, characterization of non-genetic 
drivers and the immune state of BRAFi-resistance is needed to complement important early 
findings (33-35). 
Our study has several limitations. Sequencing was performed at three institutions with distinct 
protocols and analysis methods. Although most patients had baseline pre-treatment samples for 
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comparison, nearly 20% did not. In addition, BRAF splice variants were assessed in 65% of 
progression samples. Finally, survival in this cohort was somewhat inferior to that observed in 
phase II/III BRAFi clinical trials, likely reflecting that progression must have occurred during the 
study timeframe.  
Acquired resistance to targeted therapy remains a major unanswered challenge of cancer 
therapeutics. This study provides a comprehensive characterization of the genetic landscape of 
acquired BRAFi-resistance in advanced melanoma. Furthermore, it provides insight into the 
clinical implications of these alterations and suggests further investigation into immune and 
epigenetic changes accompanying resistance.  
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Figure Legends 
 
Figure 1: (A) Number of identified resistance mechanisms per progression sample (B) Spectrum 
of resistance mechanisms in samples with only one identified alteration (C) Spectrum of 
resistance mechanisms in samples with >1 identified alteration co-occurring in the same sample 
Legend: Green: mutation; Red: amplification; Blue: deletion; ^Distinct NRAS mutations 
identified in different samples 
 
Figure 2: Heterogeneity of resistance mechanisms within individual patients with multiple 
biopsies 
Legend: Green: mutation; Red: amplification; Blue: deletion; Black: unknown 
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